PORTFOLIO
At Dreavent, our mission is to improve human health by advancing promising new therapies for important diseases currently lacking effective treatments.
The Engine 2024, our ongoing Venture Fund, exemplifies this mission by rigorously selecting and investing in high-potential biotech companies. Our proactive evaluation process, competitive advantages, and strategic partnerships ensure that we focus on firms at the forefront of medical innovation, aiming to revolutionize treatment approaches and foster a healthier future.
Open Venture Fund: Dreavent Engine 2024
Our Mission and Fund Overview
At Dreavent, our mission is to improve human health by advancing promising new therapies for important diseases currently lacking effective treatments. In line with this mission, we are now working on The Engine 2024, Dreavent Capital’s ongoing venture fund, designed to identify and invest in the most promising biotech companies. After a thorough and rigorous selection process, we have arrived at a preliminary Master List of companies. This selection process reflects Dreavent Capital’s commitment to de-risking investments as much as possible.
Proactive Evaluation Process
Our approach involves an ongoing, proactive evaluation of high-potential companies within the U.S. biotech ecosystem. This continuous cycle ensures that we consistently identify and invest in firms that align with our stringent investment criteria.
Competitive Advantages
What makes us different and unique are our competitive advantages:
Proactive Seeking vs. Traditional Passive Approach
We actively seek out investment opportunities rather than waiting for them to come to us, ensuring we capture the best potential investments.
Boston Biotech Forums Network
Our extensive network, cultivated through the Boston Biotech Forums led by our Manager, Wendy Nelson, spans both coasts and five cities, providing us with invaluable resources, expertise, and market access, significantly boosting the success potential of our portfolio companies.
Large Pharma Co-Investments
We partner with major pharmaceutical companies to maximize success probability and improve efficiency, providing strong validation and resources to our portfolio companies.
Portfolio Design
We focus on early clinical stage companies that are near proof of concept, ensuring a clearer path to market and higher potential returns.
Investment Philosophy
Our investment philosophy is guided by strict criteria to ensure we target high-potential biotech companies:
At Least One Large Pharma Company in the Cap Table
Insight: In the last 500 company failures, only 20 had one pharma company in their cap table, and only 4 had more than one large pharma involved. This underscores the importance of substantial pharma backing to mitigate risks and bolster success.
At Least One Established VC with a Successful Track Record
Insight: Among the last 500 failed companies, only 14 had more than one well-known biotech VC in their cap table. This highlights the importance of having reputable VC support to drive company growth and stability.
No Drug Discovery Stage or Early Preclinical Companies
We avoid investing in companies at the drug discovery stage or early preclinical phase due to the high risks and extended timelines associated with these stages.
Focus on Therapeutic Modalities with Commercial Precedence
We target investments in Immunology & Inflammation, Oncology, Cardiovascular & Metabolic, and Neuroscience, with a particular emphasis on Immunology and Inflammation due to its broad impact on disease treatment and innovation potential.
Expertise and Strategic Partnership
Our team brings decades of experience and a track record of successful exits. We have cultivated strategic partnerships with major pharmaceutical companies and top venture capitalists, enhancing our access to high-quality investments and demonstrating our strong industry connections.
Join Us
Do you want to be part of our mission to achieve superior returns through biotech venture investments? Join us in supporting and advancing the most promising therapeutics in clinical testing. Be part of the effort as we realize key clinical data read-outs that will determine each program’s likelihood of becoming a commercial success.
For more detailed information, please fill in the form here.
Strategic Co-Investments with Industry Leaders
Dreavent collaborates with some of the largest pharmaceutical companies and financial venture capitalists in the industry. This co-investment strategy not only underscores our reliability but also demonstrates our strong connections within the sector. Partnering with these major players, we gain insights and access to high-quality investment opportunities, reflecting our solid standing in the biotech community.
Our ability to co-invest with leading pharmaceutical firms and financial VCs allows us to access exclusive deals typically reserved for the biggest names in the industry. This level of access is a testament to our well-established network and the trust we have earned. It positions us uniquely, ensuring we are at the forefront of innovative healthcare investments and contributing significantly to advancing the biotech landscape.
